search button

Oral low-dose dexamethasone for androgen-independent prostate cancer patients

  • Authors:
    • Akira Komiya
    • Masaki Shimbo
    • Hiroyoshi Suzuki
    • Takashi Imamoto
    • Tomonori Kato
    • Satoshi Fukasawa
    • Naoto Kamiya
    • Yukio Naya
    • Ikuo Mori
    • Tomohiko Ichikawa

  • View Affiliations

  • Published online on: January 1, 2010     https://doi.org/10.3892/ol_00000013
  • Pages: 73-79
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We retrospectively evaluated the outcome of oral low-dose dexamethasone (DXM) therapy for androgen-independent prostate cancer (AIPC). Between January 1999 and April 2006, 99 consecutive patients with AIPC were enrolled in this study. The median patient age was 70 years (range 46-86), and the median pretreatment prostate-specific antigen (PSA) level was 243 ng/ml (range 8.2-29600). Median follow-up was 41.9 months (range 11.4-170.4). Upon biochemical failure, patients were treated with oral low-dose DXM. A total of 40 of the 99 cases (40.4%) showed a ≥50% decrease in serum PSA levels (PSA responders). Twenty-five cases (25.2%) showed a <50% decrease in PSA, and the remaining 34 cases (34.3%) had increased PSA levels (PSA non-responders). The median PSA progression-free survival was 3.0 (range 0-27) and 8.0 months (range 2-27) for the entire cohort and PSA responders, respectively. The PSA responders had a significantly increased survival (median 30.1 months) compared to the non-responders (median 8.8 months, P<0.001). Of the 34 patients who were under pain control for bone metastases before the administration of DXM, 23 (67.6%) were able to discontinue the regular use of analgesics. The PSA responders also showed an increase in hemoglobin levels. The change in serum interleukin-6 levels was significantly associated with a response to DXM (P=0.0065). Severe adverse events of DXM were rare. Clinicopathological factors predicting the PSA response to DXM were age, time from initial androgen deprivation therapy to DXM and PSA velocity prior to DXM. In conclusion, oral low-dose DXM led to an acceptable PSA response in patients with AIPC. Thus, this therapy may be an effective and safe alternative for the treatment of AIPC, particularly for patients who are not favourable candidates for chemotherapy.
View Figures
View References

Related Articles

Journal Cover

January-February 2010
Volume 1 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Komiya A, Shimbo M, Suzuki H, Imamoto T, Kato T, Fukasawa S, Kamiya N, Naya Y, Mori I, Ichikawa T, Ichikawa T, et al: Oral low-dose dexamethasone for androgen-independent prostate cancer patients . Oncol Lett 1: 73-79, 2010.
APA
Komiya, A., Shimbo, M., Suzuki, H., Imamoto, T., Kato, T., Fukasawa, S. ... Ichikawa, T. (2010). Oral low-dose dexamethasone for androgen-independent prostate cancer patients . Oncology Letters, 1, 73-79. https://doi.org/10.3892/ol_00000013
MLA
Komiya, A., Shimbo, M., Suzuki, H., Imamoto, T., Kato, T., Fukasawa, S., Kamiya, N., Naya, Y., Mori, I., Ichikawa, T."Oral low-dose dexamethasone for androgen-independent prostate cancer patients ". Oncology Letters 1.1 (2010): 73-79.
Chicago
Komiya, A., Shimbo, M., Suzuki, H., Imamoto, T., Kato, T., Fukasawa, S., Kamiya, N., Naya, Y., Mori, I., Ichikawa, T."Oral low-dose dexamethasone for androgen-independent prostate cancer patients ". Oncology Letters 1, no. 1 (2010): 73-79. https://doi.org/10.3892/ol_00000013